Nakashima Kuniki, Kumakura Hisao, Funada Ryuichi, Matsuo Yae, Sakata Kimimasa, Ichikawa Akiko, Iwasaki Toshiya, Ichikawa Shuichi
Department of Cardiovascular Surgery, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital), Shibukawa, Gunma, Japan.
Department of Cardiovascular Medicine, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital), Shibukawa, Gunma, Japan.
Ann Vasc Dis. 2021 Sep 25;14(3):236-243. doi: 10.3400/avd.oa.21-00045.
This study aimed to examine the relationship between microalbuminuria and long-term life expectancy or limb events in patients with peripheral arterial disease (PAD). A prospective cohort study was performed in 714 patients with PAD. The primary outcomes were cardiovascular or cerebrovascular death (CCVD) and all-cause death (AD), and secondary outcomes were major adverse cardiovascular events (MACE) and cardiovascular and/or limb events (CVLE). The 5, 10, and 15 year survival rates were 82.4%, 53.1%, and 33.0%, respectively. The prevalence of patients with increased microalbuminuria was 39.2%. Higher microalbuminuria, age, C-reactive protein (CRP), lower serum albumin, estimated glomerular filtration rate (eGFR), ankle-brachial pressure index (ABI), diabetes, cerebral infarction, and coronary heart disease (CHD) were associated with CCVD; higher microalbuminuria, age, CRP, D-dimer, lower serum albumin, eGFR, and critical limb ischemia were related to AD; higher microalbuminuria, age, CRP, lower serum albumin, ABI, diabetes, and CHD were related to MACE; higher microalbuminuria, age, lower ABI, cerebral infarction, and CHD were related to CVLE in Cox multivariate analyses (p<0.05). Statins reduced CCVD, AD, MACE, and CVLE (p<0.001). Higher microalbuminuria was a significant predictor for CCVD, AD, MACE, and CVLE in PAD patients.
本研究旨在探讨外周动脉疾病(PAD)患者微量白蛋白尿与长期预期寿命或肢体事件之间的关系。对714例PAD患者进行了一项前瞻性队列研究。主要结局为心血管或脑血管死亡(CCVD)和全因死亡(AD),次要结局为主要不良心血管事件(MACE)以及心血管和/或肢体事件(CVLE)。5年、10年和15年生存率分别为82.4%、53.1%和33.0%。微量白蛋白尿增加患者的患病率为39.2%。较高的微量白蛋白尿、年龄、C反应蛋白(CRP)、较低的血清白蛋白、估计肾小球滤过率(eGFR)、踝臂压力指数(ABI)、糖尿病、脑梗死和冠心病(CHD)与CCVD相关;较高的微量白蛋白尿、年龄、CRP、D-二聚体、较低的血清白蛋白、eGFR和严重肢体缺血与AD相关;较高的微量白蛋白尿、年龄、CRP、较低的血清白蛋白、ABI、糖尿病和CHD与MACE相关;较高的微量白蛋白尿、年龄、较低的ABI、脑梗死和CHD与Cox多变量分析中的CVLE相关(p<0.05)。他汀类药物可降低CCVD、AD、MACE和CVLE(p<0.001)。较高的微量白蛋白尿是PAD患者CCVD、AD、MACE和CVLE的重要预测指标。
Eur Heart J Qual Care Clin Outcomes. 2019-1-1
Ont Health Technol Assess Ser. 2010
Eur Heart J Qual Care Clin Outcomes. 2017-7-1
Eur Heart J Qual Care Clin Outcomes. 2019-1-1
Eur Heart J Qual Care Clin Outcomes. 2017-7-1
Eur Heart J Cardiovasc Imaging. 2016-1-12